Page last updated: 2024-11-06

imidazo(1,2-a)pyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Imidazo(1,2-a)pyridine is a bicyclic heterocyclic compound that serves as a core structure for a wide range of bioactive molecules. It is a versatile scaffold with diverse pharmacological activities, including anti-inflammatory, antimicrobial, anticancer, and anti-HIV properties. The compound is often synthesized through various methods, including the condensation of 2-aminopyridines with α-haloketones or aldehydes. Imidazo(1,2-a)pyridine derivatives have been extensively studied due to their potential therapeutic applications. Their biological activities are attributed to their ability to interact with various biological targets, such as enzymes, receptors, and DNA. The presence of the imidazole and pyridine rings provides opportunities for structural modifications and optimization of pharmacological properties. The synthesis and evaluation of imidazo(1,2-a)pyridine derivatives continue to be an active area of research in medicinal chemistry.'

imidazo(1,2-a)pyridine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID78960
CHEMBL ID377488
SCHEMBL ID7883
MeSH IDM0041635

Synonyms (37)

Synonym
imidazo(1,2-a)pyridine
g18zbv2hxa ,
unii-g18zbv2hxa
imidazo[1,2-a]pyridine
imidazo[1,2-a]pyridine, 99%
AKOS005144331
CHEMBL377488 ,
STK894053
274-76-0
4h-imidazo[1,2-a]pyridine
1h-imidazo[1,2-a]pyridine
EN300-55659
A819085
h-imidazo[1,2-a]pyridine
BP-13302
FT-0631896
BBL021341
SCHEMBL7883
UTCSSFWDNNEEBH-UHFFFAOYSA-N
imidazo [1,2-a] pyridine
imidazo[l,2-a]pyridine
imidazolo[1,2-a]pyridine
imidazo[1,2-a]-pyridine
AM86817
AC-23329
I0922
DTXSID80181821
J-521496
J-016780
mfcd00005553
AS-17415
Q27278572
imidazo[1
bdbm50269837
SY024154
CS-W016589
Z838912682

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" As a result, we identified potent, selective, and orally bioavailable ASK1 inhibitors for wide range of therapeutic targets."( Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
Fujitani, Y; Inoue, Y; Kawamoto, T; Nakagawa, H; Okada, K; Suzuki, H; Takekawa, S; Terao, Y; Uchikawa, O; Yamamoto, Y; Yao, S; Yashiro, H; Yoshikawa, M, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
"21microM, respectively, and suppressed tumor growth by 37% in a mouse HeLa xenograft model when dosed intraperitoneally at 25mg/kg."( Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.
Hayakawa, M; Ishikawa, N; Kaizawa, H; Kawaguchi, K; Koizumi, T; Ohishi, T; Ohta, M; Okada, M; Parker, P; Raynaud, FI; Tsukamoto, S; Waterfield, MD; Workman, P; Yamano, M, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1489209Displacement of [3H]-DPCPX from A1 receptor in rat whole brain membrane2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Imidazo[1,2-α]pyridines possess adenosine A
AID262224Dissociation constant, pKa of the compound2006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
8-Fluoroimidazo[1,2-a]pyridine: synthesis, physicochemical properties and evaluation as a bioisosteric replacement for imidazo[1,2-a]pyrimidine in an allosteric modulator ligand of the GABA A receptor.
AID780208Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.
AID780207Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.
AID1489210Displacement of [3H]-NECA from A2A receptor in rat striatal membrane in presence of A1 receptor agonist N6-cyclopentyladenosine2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Imidazo[1,2-α]pyridines possess adenosine A
AID780210Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.
AID262225Distribution coefficient, log D at pH 7.42006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
8-Fluoroimidazo[1,2-a]pyridine: synthesis, physicochemical properties and evaluation as a bioisosteric replacement for imidazo[1,2-a]pyrimidine in an allosteric modulator ligand of the GABA A receptor.
AID780209Selectivity index, ratio of CC50 for mouse J774.1 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.
AID780211Antimicrobial activity against Leishmania donovani MHOM/IN/00/DEVI promastigotes after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.
AID551809Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
AID1615596Lipophilicity, log D of the compound2019European journal of medicinal chemistry, Nov-01, Volume: 181Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.
AID1615597Partition coefficient, log P of the compound2019European journal of medicinal chemistry, Nov-01, Volume: 181Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.
AID1201286Inhibition of FLT3 (unknown origin) using FAM-EPLYWSFPA as substrate at 20 uM preincubated for 60 mins followed by substrate addition by microfluidics assay in presence of 190 uM ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (91)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.10)18.7374
1990's4 (4.40)18.2507
2000's16 (17.58)29.6817
2010's62 (68.13)24.3611
2020's8 (8.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.99 (24.57)
Research Supply Index4.55 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index41.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (4.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other90 (95.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]